Elutia is at the forefront of medical innovation with its proprietary drug-eluting biomaterial platforms designed to enhance patient care and address complications associated with medical device implants. Their flagship products, CanGaroo and SimpliDerm, integrate natural biologic materials with extended antibiotic release to improve the outcomes of device implantation and soft tissue reconstruction. CanGaroo, specifically designed for implantable electronic devices, utilizes an acellular envelope made from porcine small intestine submucosa extracellular matrix (SIS ECM). This technology promotes a natural healing response, reduces inflammation, and supports the formation of healthy, vascularized tissue around the implant, thereby mitigating risks such as device migration and erosion.

SimpliDerm, on the other hand, is a human acellular dermal matrix aimed at soft tissue reconstruction. Both products are engineered to ensure implant stability and promote wound healing while minimizing fibrotic responses that can lead to adverse outcomes. Elutia's commitment to humanizing medicine is evident in their mission to provide solutions that not only facilitate recovery but also enhance the overall quality of life for patients undergoing surgical procedures. Through these innovative biomaterials, Elutia is addressing critical challenges in the medical device landscape, ultimately striving to improve patient outcomes and reduce healthcare costs.

United States

At Elutia we’re pioneering the future of patient care. Our proprietary drug-eluting biomaterial platforms stand at the forefront of medical innovation.

Elutia

Company Details